Clinical trials: Prostate Cancer Metastatic Disease
Prostate Cancer
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant prostate cancer.
- Trial name
- NCT00916123
- Testing
- Docetaxel, Prednisone, 177Lu-J591
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer, Bone Metastases
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
- Trial name
- NCT02826382
- Testing
- [68Ga]P15-041
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Five Eleven Pharma, Inc.
Metastatic Castration-resistant Prostate Cancer
Phase 0/1 Study of 212Pb-NG001 in mCRPC
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
- Trial name
- NCT05725070
- Testing
- 212Pb-NG001
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- ARTBIO Inc.
Metastatic Hormone Sensitive Prostate Cancer
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC).
- Trial name
- China ARCHES (NCT04076059)
- Testing
- Enzalutamide, Androgen deprivation therapy (ADT)
- Where
- 28 sites in China
- Volunteers
- 180 people
- Sponsor
- Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Progressive Metastatic Castrate-Resistant Prostate Cancer
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- AARDVARC (NCT04495179)
- Testing
- AZD4635, Durvalumab, Cabazitaxel
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Metastatic Prostate Cancer
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
- Trial name
- NCT02051218
- Testing
- Denosumab (reduced dosing), Denosumab (standard dosing)
- Where
- 50 sites in Austria, Germany and 1 more
- Volunteers
- 1,380 people
- Sponsor
- Swiss Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05828082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Castrate Sensitive Prostate Cancer, Metastatic Prostate Cancer
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
This study consists of two home-based exercise programs: a stationary exercise bicycle intervention (Arm A), and a walking intervention (Arm B).
- Trial name
- NCT06429813
- Testing
- Home-Based Exercise Intervention - Walking, Home-Based Exercise Intervention - HIIT Cycling
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Paul Viscuse
Prostate Cancer Metastatic
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and…
- Trial name
- LUTRAC (NCT06260410)
- Testing
- Blood draw for ctDNA and circulating tumor cell collection.
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Erasmus Medical Center
Castration-Resistant Prostate Cancer
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
This is a Phase 1, open-label, multicenter study of KPG-121 administered orally once daily (QD) in 28-day treatment cycles to adult subjects.
- Trial name
- NCT03569280
- Testing
- Enzalutamide or Abiraterone or Apalutamid
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kangpu Biopharmaceuticals, Ltd.
Castration-resistant Prostate Cancer
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy.
- Trial name
- NCT05534646
- Testing
- AR Blockade, Carotuximab
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- Edwin Posadas, MD
Cancer
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
This study is being conducted to characterize the safety and recommended phase 2 dose (RP2D) of combining afuresertib, independently with 2 approved drugs: enzalutamide (Xtandi®, "Xtandi is a trademark of Astellas Pharma, Inc." )…
- Trial name
- NCT02380313
- Testing
- Afuresertib, Enzalutamide, Abiraterone
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
An open, multicenter and prospective study to evaluate the impact of the treatment with zoledronic acid 4 mg, on the quality of life and the skeletal-related events in patients with prostate cancer and bone metastasis that…
- Trial name
- NCT00237146
- Testing
- Zoledronic acid
- Where
- Venezuela
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045227
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or…
- Trial name
- NCT03418324
- Testing
- TRC105, Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Castration-resistant Prostate Cancer, Androgen Deprivation Therapy
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer…
- Trial name
- NCT03672396
- Testing
- Home-based exercise
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Conditions
- Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00020046
- Testing
- docetaxel, thalidomide
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Prostate Cancer
Efficacy Study of ABR-215050 to Treat Prostate Cancer
To investigate ABR-215050 as a possible treatment for prostate cancer.
- Trial name
- NCT00560482
- Testing
- ABR-215050, tasquinimod
- Where
- 65 sites in United States, Canada and 1 more
- Volunteers
- 206 people
- Sponsor
- Active Biotech AB